Vanda Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 203
- Market Cap
- $311.8M
- Introduction
Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.
Tolerability and Pharmacokinetics of Iloperidone in Adolescent Patients
- Conditions
- Safety and Tolerability of Iloperidone
- Interventions
- First Posted Date
- 2011-12-19
- Last Posted Date
- 2016-06-13
- Lead Sponsor
- Vanda Pharmaceuticals
- Target Recruit Count
- 33
- Registration Number
- NCT01495169
- Locations
- 🇺🇸
Novartis Investigative Site, Salt Lake City, Utah, United States
Effects of Smoking, Age and Body Size on Pharmacokinetics, Safety and Tolerability on Tasimelteon in Healthy Subjects
- First Posted Date
- 2011-11-22
- Last Posted Date
- 2014-02-17
- Lead Sponsor
- Vanda Pharmaceuticals
- Target Recruit Count
- 60
- Registration Number
- NCT01477619
- Locations
- 🇺🇸
Bio-Kinetic Clinical Applications, Springfield, Missouri, United States
Withdrawal Study to Demonstrate the Maintenance Effect in the Treatment of Non-24-Hour Sleep-Wake Disorder
- Conditions
- Non-24-Hour Sleep-Wake Disorder
- Interventions
- Drug: Placebo
- First Posted Date
- 2011-09-08
- Last Posted Date
- 2014-10-10
- Lead Sponsor
- Vanda Pharmaceuticals
- Target Recruit Count
- 20
- Registration Number
- NCT01430754
- Locations
- 🇺🇸
PAB Clinical Research Inc., Brandon, Florida, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Todd J. Swick, M.D., P.A., Houston, Texas, United States
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
- First Posted Date
- 2011-09-05
- Last Posted Date
- 2015-06-19
- Lead Sponsor
- Vanda Pharmaceuticals
- Target Recruit Count
- 507
- Registration Number
- NCT01428661
- Locations
- 🇺🇸
Vanda Investigational Site, Brown Deer, Wisconsin, United States
Tasimelteon for the Treatment of Non-24-hour Sleep-Wake Disorder (N24HSWD) in Blind Individuals With no Light Perception
- First Posted Date
- 2011-09-05
- Last Posted Date
- 2015-04-21
- Lead Sponsor
- Vanda Pharmaceuticals
- Target Recruit Count
- 200
- Registration Number
- NCT01429116
- Locations
- 🇺🇸
SleepMed, Inc. - Columbia, Columbia, South Carolina, United States
🇺🇸SDS Clinical Trials Inc., Orange, California, United States
🇺🇸VA Palo Alto Health Care System/PAIRE (San Fransisco Bay Area), Palo Alto, California, United States
A Study to Assess the Effect Tasimelteon on the Cytochrome P450 3A4 and 2C8 Enzymes in Healthy Subjects
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2011-07-26
- Last Posted Date
- 2014-02-17
- Lead Sponsor
- Vanda Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT01402076
- Locations
- 🇺🇸
Bio-Kinetic Clinical Applications, Springfield, Missouri, United States
Relapse Prevention Study in Patients With Schizophrenia
- First Posted Date
- 2011-02-08
- Last Posted Date
- 2023-07-17
- Lead Sponsor
- Vanda Pharmaceuticals
- Target Recruit Count
- 635
- Registration Number
- NCT01291511
- Locations
- 🇺🇦
Vanda Investigive Site, Kharkiv, Ukraine
🇺🇦Vanda Investigative Site, Vinnytsya, Ukraine
Pharmacokinetics of Tasimelteon in Subjects With Mild or Moderate Hepatic Impairment
- First Posted Date
- 2011-01-06
- Last Posted Date
- 2014-02-17
- Lead Sponsor
- Vanda Pharmaceuticals
- Target Recruit Count
- 29
- Registration Number
- NCT01271387
- Locations
- 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
Safety Study of Tasimelteon for Treatment of Non-24-Hour-Sleep-Wake Disorder in Blind Individuals With No Light Perception
- Conditions
- Non 24 Hour Sleep Wake Disorder
- Interventions
- First Posted Date
- 2010-10-11
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Vanda Pharmaceuticals
- Target Recruit Count
- 140
- Registration Number
- NCT01218789
Patient Registry of Blind Subjects With Sleep-related Problems
- Conditions
- Sleep-wake Disorder in Blind Individuals
- Interventions
- Other: Data collection on blindness and sleep problems
- First Posted Date
- 2010-09-06
- Last Posted Date
- 2020-06-24
- Lead Sponsor
- Vanda Pharmaceuticals
- Target Recruit Count
- 10000
- Registration Number
- NCT01195558
- Locations
- 🇺🇸
Vanda Pharmaceuticals, Washington, District of Columbia, United States